PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28282887-3 2017 In fact, a minimal chain length of 18 saccharides units, including an antithrombin (AT) binding pentasaccharide, is mandatory to form the active ternary complex for LMWH obtained by alkaline beta-elimination (e.g., enoxaparin). Enoxaparin 215-225 serpin family C member 1 Homo sapiens 70-82 26758598-8 2016 The utility of this approach is demonstrated for tetrasaccharide SEC fractions of the low molecular weight heparin drug enoxaparin facilitating the isolation and characterization of an unsaturated 3-O-sulfated tetrasaccharide containing a portion of the antithrombin-III binding sequence. Enoxaparin 120-130 serpin family C member 1 Homo sapiens 254-270 17600038-8 2007 CONCLUSIONS: When compared with UFH, enoxaparin was associated with superior efficacy as adjunctive antithrombin therapy among >49 000 patients across the ACS spectrum. Enoxaparin 37-47 serpin family C member 1 Homo sapiens 100-112 26280926-10 2015 These results were further confirmed by orthogonal analytical techniques, including NMR, which revealed compositional differences of oligosaccharides both in low- and high-affinity antithrombin fractions of enoxaparin. Enoxaparin 207-217 serpin family C member 1 Homo sapiens 181-193 17621651-0 2007 Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin. Enoxaparin 92-102 serpin family C member 1 Homo sapiens 66-78 17621651-2 2007 We evaluated the incidence and consequences of periprocedural macroscopic thrombus formation on PCI equipment following antithrombin therapy with enoxaparin. Enoxaparin 146-156 serpin family C member 1 Homo sapiens 120-132 17621651-3 2007 Between April 2003 and December 2004, all patients undergoing cardiac catheterization following antithrombin therapy with enoxaparin were evaluated. Enoxaparin 122-132 serpin family C member 1 Homo sapiens 96-108 17621651-11 2007 Percutaneous coronary intervention following antithrombin therapy with enoxaparin is associated with a 5% incidence of macroscopic thrombus formation on PCI equipment. Enoxaparin 71-81 serpin family C member 1 Homo sapiens 45-57 24375987-0 2014 Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis. Enoxaparin 95-105 serpin family C member 1 Homo sapiens 28-44 24375987-5 2014 PROCEDURE: This retrospective study compared time to therapeutic anti-Xa levels in patients <1 year of age receiving enoxaparin with AT3 (Group 1) and without AT3 (Group 2) for treatment of thrombosis. Enoxaparin 120-130 serpin family C member 1 Homo sapiens 136-139 24616065-3 2014 ACE is used in this work to measure the relative AT-III binding affinities of the low molecular weight heparins (LWMHs) dalteparin, enoxaparin, and tinzaparin and the synthetic pentasaccharide drug fondaparinux (Arixtra). Enoxaparin 132-142 serpin family C member 1 Homo sapiens 49-55 17489664-1 2007 Enoxaparin is a low-molecular-weight heparin (LMWH) derivative that exerts its anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin 0-10 serpin family C member 1 Homo sapiens 110-126 16675258-10 2006 Heparin was given during cardiopulmonary bypass to maintain an activated clotting time above 480 s. RESULTS: Patients in the enoxaparin group needed more heparin to maintain an activated clotting time above 480 s, and had higher heparin concentrations and lower antithrombin values compared with control patients. Enoxaparin 125-135 serpin family C member 1 Homo sapiens 262-274 16685318-1 2006 BACKGROUND: Subcutaneous enoxaparin is increasingly employed as the antithrombin of choice in non-ST elevation myocardial infarction and in conjunction with various fibrinolytic regimens in acute ST elevation myocardial infarction (STEMI). Enoxaparin 25-35 serpin family C member 1 Homo sapiens 68-80 15957976-5 2005 Antithrombin therapy with LMWH or UFH has the highest-level recommendation (IA) in the 2002 professional guidelines for the management of unstable angina and non-ST-elevation myocardial infarction, where enoxaparin has a IIA recommendation over UFH unless early coronary artery bypass surgery is planned. Enoxaparin 204-214 serpin family C member 1 Homo sapiens 0-12 11287128-2 2001 Titration of antithrombin with both low molecular weight heparin (LMWH) (enoxaparin, fragmin and ardeparin) and unfractionated heparin (UFH) produced an equivalent fluorescence increase and indicates similar affinity of all heparin preparations to antithrombin. Enoxaparin 73-83 serpin family C member 1 Homo sapiens 13-25 15210403-13 2004 In most instances LMWH (dalteparin, enoxaparin, nadroparin) treatment for DVT may be given once daily at a fixed dose without any harm, based on a prolonged antithrombin activity. Enoxaparin 36-46 serpin family C member 1 Homo sapiens 157-169 11812067-12 2002 These findings regarding enoxaparin add to the data to be considered by clinicians when selecting an antithrombin for the acute phase of management of unstable angina/non-ST elevation myocardial infarction. Enoxaparin 25-35 serpin family C member 1 Homo sapiens 101-113 11755953-3 2001 We have estimated the concentration of circulating thrombin-antithrombin (TAT) complex in patients subjected to transperitoneal nephrectomy and randomized into controls and who received 40-mg enoxaparin 12 h before and 12 h after the operation and then once daily for 7 days. Enoxaparin 192-202 serpin family C member 1 Homo sapiens 60-72 15860994-6 2005 Fibrinolytic therapy, in combination with adjunctive antithrombin therapy that is simpler and quicker to administer (e.g., tenecteplase with enoxaparin), may be more efficacious and easier to use than regimens involving unfractionated heparin. Enoxaparin 141-151 serpin family C member 1 Homo sapiens 53-65 16124953-9 2005 A nonsignificant trend toward higher rates of major bleeding was seen at 7 days for enoxaparin-treated patients, in both the overall safety population and the population of patients who did not receive antithrombin treatment before randomization, but there was no difference in blood transfusions. Enoxaparin 84-94 serpin family C member 1 Homo sapiens 202-214 15238596-0 2004 Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. Enoxaparin 65-75 serpin family C member 1 Homo sapiens 106-118 14728009-1 2001 Enoxaparin (enoxaparin sodium) is a low-molecular-weight heparin that binds to and increases the activity of antithrombin III. Enoxaparin 0-10 serpin family C member 1 Homo sapiens 109-125 14728009-1 2001 Enoxaparin (enoxaparin sodium) is a low-molecular-weight heparin that binds to and increases the activity of antithrombin III. Enoxaparin 12-29 serpin family C member 1 Homo sapiens 109-125 8165617-6 1993 Clexane (M(r) = 4,500) also bound antithrombin III, but both histidine-rich glycoprotein and vitronectin were quantitatively significant neutralising proteins. Enoxaparin 0-7 serpin family C member 1 Homo sapiens 34-50 31986476-0 2020 Supplementation with antithrombin III ex vivo optimizes enoxaparin responses in critically injured patients. Enoxaparin 56-66 serpin family C member 1 Homo sapiens 21-37 1848441-8 1991 The anti Xa activity peak seen after adding AT III to plasma was much higher with heparin than with enoxaparin. Enoxaparin 100-110 serpin family C member 1 Homo sapiens 44-50 1848441-9 1991 In urine, biological activities, measured with AT III supplementation, were higher with enoxaparin than with heparin. Enoxaparin 88-98 serpin family C member 1 Homo sapiens 47-53 34790076-3 2021 This case report describes a critically ill premature infant with a progressive, occlusive inferior vena cava thrombus who received supplemental ATIII during enoxaparin treatment. Enoxaparin 158-168 serpin family C member 1 Homo sapiens 145-150 30262570-10 2019 The 5-year event-free survival was 80.9+-2.2% among patients assigned to antithrombin compared to 85.9+-2.0% in the unfractionated heparin group (P=0.06), and 86.2+-2.0% in the enoxaparin group (P=0.10). Enoxaparin 177-187 serpin family C member 1 Homo sapiens 73-85 30181723-0 2018 Effect of Exogenous Antithrombin Administration on Anti-Xa Levels in Infants Treated With Enoxaparin. Enoxaparin 90-100 serpin family C member 1 Homo sapiens 20-32 30181723-1 2018 OBJECTIVES: Determine the effect of exogenous antithrombin III administration on low molecular weight heparin anti-Xa levels in the context of enoxaparin dosing in infants. Enoxaparin 143-153 serpin family C member 1 Homo sapiens 46-62 30181723-8 2018 The median dose of antithrombin III was 50 units/kg and was administered when patients were receiving a median enoxaparin dose of 1.71 mg/kg. Enoxaparin 111-121 serpin family C member 1 Homo sapiens 19-35 30181723-10 2018 CONCLUSIONS: These results demonstrated that administration of exogenous antithrombin III to infants who were being treated with enoxaparin results in a significant increase in anti-Xa levels. Enoxaparin 129-139 serpin family C member 1 Homo sapiens 73-89 30181723-12 2018 However, antithrombin III supplementation could be considered a potential option for patients who are unable to adequately achieve therapeutic anti-Xa levels with enoxaparin alone. Enoxaparin 163-173 serpin family C member 1 Homo sapiens 9-25 29031112-8 2017 With the method, the molar percentage of the ATIII-binding site of enoxaparin from different batches and different manufactures were measured and compared. Enoxaparin 67-77 serpin family C member 1 Homo sapiens 45-50